SK Bioscience Establishes Dedicated Medical and Pharmaceutical Team to Develop Expertise-Based Business Strategies

Hiring of Hye-Young Kim, Medical Director Formerly at Korea Pfizer

Medical Director Hye-young Kim, SK Bioscience.

[Asia Economy Reporter Lee Gwan-joo] SK Bioscience has established a dedicated medical and pharmaceutical organization to enhance the competitiveness of its domestic and international business strategies.

On the 21st, SK Bioscience announced the establishment of the 'Medical Affair' department, responsible for medical and academic affairs. The appointed executive is MD (Medical Director) Hye-young Kim, who previously worked at the multinational pharmaceutical company Pfizer Korea.

The newly established Medical Affair department is responsible for setting the medical direction of research and development (R&D) projects and building data on the efficacy and safety of pharmaceuticals from an academic perspective. It also handles the dissemination of accumulated pharmaceutical information both internally and externally, expands academic networks with domestic and international medical experts, and plans and executes medical strategies.

MD Kim, newly recruited this time, is an expert in the medical field who graduated from Seoul National University College of Medicine and obtained master's and doctoral degrees from the same graduate school. She has a background as a clinical professor in the Department of Anesthesiology and Pain Medicine at Seoul National University Hospital, served as head of the medical department at Mundipharma Korea, and was an executive director at Pfizer Korea, possessing not only academic experience but also diverse practical experience and networks as an executive in a multinational pharmaceutical company.

SK Bioscience stated, "Through the establishment of this organization and the recruitment of a new executive, we expect to strengthen the global network, which is a core part of our mid- to long-term growth strategy, and enhance competitiveness in the R&D field."

This content was produced with the assistance of AI translation services.